{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-054632","form_type":"8-K","ticker":"IRD","cik":"0001228627","company_name":"Opus Genetics, Inc.","filed_at":"2023-11-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.463071+00:00","generated_at":"2026-06-07T21:21:10.521725+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Ocuphire Pharma appoints Joseph Schachle COO; $400K salary, 300K option grant","bullets":["Joseph Schachle appointed COO effective Nov 27, 2023; previously COO of Opus Genetics.","Base salary $400K, target annual bonus 45% of base, 300K stock option grant.","Stock option vests 25% on 1-year anniversary, remaining monthly over 36 months.","Appointment part of strategic initiative to advance lead retina asset APX3330 into registrational studies.","Severance: 9 months salary continuation plus COBRA reimbursement if terminated without cause or for good reason."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-054632","json":"https://secwatch.observer/filing/0001140361-23-054632.json","markdown":"https://secwatch.observer/filing/0001140361-23-054632.md","text":"https://secwatch.observer/filing/0001140361-23-054632.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1228627/000114036123054632/0001140361-23-054632-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1228627/000114036123054632/ef20015189_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T21:21:10.521725+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1ca9e99771","claim":"Joseph Schachle was appointed as Chief Operating Officer at Opus Genetics, Inc..","evidence_excerpt":"On November 22, 2023, the Board of Directors (the “Board”) of Ocuphire Pharma, Inc. (the “Company”) appointed Joseph Schachle, age 58, as the Company’s Chief Operating Officer, effective as of November 27, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1228627/000114036123054632/0001140361-23-054632-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Operating Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}